Navocaftor is under clinical development by Sionna Therapeutics and currently in Phase II for Cystic Fibrosis.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

MV-130 is under clinical development by Inmunotek and currently in Phase II for Lower Respiratory Tract Infections.

Vidofludimus calcium is under clinical development by Immunic and currently in Phase III for Coronavirus Disease 2019 (COVID-19).

Ifinatamab deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase II for Neuroendocrine Tumors.

ABSK-043 is under clinical development by Abbisko Therapeutics and currently in Phase II for Non-Small Cell Lung Cancer.

Raludotatug deruxtecan is under clinical development by Daiichi Sankyo and currently in Phase III for Peritoneal Cancer.

PR-15 is under clinical development by advanceCor and currently in Phase II for Coronary Artery Disease (CAD) (Ischemic Heart Disease).

Imvotamab is under clinical development by IGM Biosciences and currently in Phase I for Idiopathic Inflammatory Myopathy (IIM).

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, ...

TNB-738 is under clinical development by Ancora Biotech and currently in Phase I for Unspecified Immunological Disorders.